Found: 4
Select item for more details and to access through your institution.
Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration.
- Published in:
- International Journal of Retina & Vitreous, 2023, v. 9, n. 1, p. 1, doi. 10.1186/s40942-023-00445-0
- By:
- Publication type:
- Article
One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents.
- Published in:
- Clinical Ophthalmology, 2023, v. 17, p. 3601, doi. 10.2147/OPTH.S432957
- By:
- Publication type:
- Article
Comparison of Face-down Positioning Durations Following Silicone Oil Tamponade.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab.
- Published in:
- Ophthalmology & Therapy, 2023, v. 12, n. 5, p. 2397, doi. 10.1007/s40123-023-00741-w
- By:
- Publication type:
- Article